|View printer-friendly version|
|December 24, 2007 2:15 p.m.|
|Teva Announces Launch of Generic Protonix® Tablets, 20 Mg and 40 Mg Company Increases 2007 EPS Guidance to Between $2.34 and $2.36 Company to Hold Conference Call at 8:45 A.M. Eastern Time|
Jerusalem, Israel, December 24, 2007 - Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that it has commercially launched Pantoprazole Sodium Delayed Release (DR) Tablets, 20 mg and 40 mg, which are AB-rated to Wyeth's erosive GERD treatment Protonix® DR Tablets. The brand product had annual sales of approximately $2.5 billion in the United States for the twelve months ended September 30, 2007, based on IMS sales data.